Research in obese mice demonstrated that AOD-9604 increases beta-3 adrenergic receptor RNA expression, restoring levels comparable to those in lean mice
Intramuscular injections may be preferred for deeper absorption , while subcutaneous options may offer ease of use in at-home settings when clinically appropriate
No hepatic safety signal has been identified, a finding of particular importance given the hepatotoxicity that led to the discontinuation of competing oral GLP-1 programs
Disclaimer This product is intended for laboratory research only and is not for human consumption.
Key Takeaways Standard research dosing for 5-amino-1-MQ typically ranges from 50-100mg daily, with some protocols extending to 200mg based on body weight and research objectives Administration routes include oral capsules, sublingual tablets, and injectable forms, each with different bioavailability profiles Timing protocols generally recommend split dosing (morning and evening) or single morning administration for optimal metabolic enzyme inhibition Cycle length in research settings commonly spans 8-12 weeks with appropriate monitoring and evaluation periods Individual factors such as body composition, metabolic rate, and research goals significantly influence optimal dosing strategies Understanding 5-Amino-1-MQ and Its Mechanism Before diving into dosing protocols, understanding how 5-amino-1-MQ functions provides essential context for determining appropriate administration strategies
